{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:30:57Z","timestamp":1787502657173,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016239","name":"University of Occupational and Environmental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17\u202fK16219"],"award-info":[{"award-number":["17\u202fK16219"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clim.2018.12.017","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T21:28:13Z","timestamp":1545168493000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"200","author":[{"given":"Maiko","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Kitanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheau Pey","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.clim.2018.12.017_bb0005","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clim.2018.12.017_bb0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2018.12.017_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.01.008","article-title":"Genetic susceptibility to SLE: recent progress from GWAS","volume":"41","author":"Cui","year":"2013","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.clim.2018.12.017_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrg2571","article-title":"Genetic susceptibility to Lupus: New Insights from fine mapping and genome-wide association studies","volume":"10","author":"Harley","year":"2009","journal-title":"Nat Rev Genet."},{"issue":"11","key":"10.1016\/j.clim.2018.12.017_bb0025","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/eji.201444622","article-title":"Autoreactivity and the positive selection of B cells","volume":"45","author":"\u00dcbelhart","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0030","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/rheumatology\/keu532","article-title":"Amplification of IL-21 signaling pathway through Bruton's tyrosine kinase in human B cell activation","volume":"54","author":"Wang","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2018.12.017_bb0035","first-page":"516","article-title":"T follicular helper cells, interleukin-21 and systemic lupus erythematosus","volume":"56","author":"Gensous","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.clim.2018.12.017_bb0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2169\/internalmedicine.46.1914","article-title":"Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases","volume":"46","author":"Tanaka","year":"2007","journal-title":"Intern. Med."},{"key":"10.1016\/j.clim.2018.12.017_bb0045","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0961203316643172","article-title":"B cell subsets, signaling and their roles in secretion of autoantibodies","volume":"25","author":"Iwata","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2018.12.017_bb0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/1756-185X.12534","article-title":"Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus","volume":"18","author":"Nakayamada","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.12.017_bb0055","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.23498","article-title":"Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95","volume":"58","author":"Jacobi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.12.017_bb0060","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.10949","article-title":"Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus","volume":"48","author":"Jacobi","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.12.017_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nrrheum.2010.68","article-title":"B cells as therapeutic targets in SLE","volume":"6","author":"Sanz","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2018.12.017_bb0070","doi-asserted-by":"crossref","first-page":"e67003","DOI":"10.1371\/journal.pone.0067003","article-title":"SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature","volume":"8","author":"Becker","year":"2013","journal-title":"PLoS One"},{"issue":"5969","key":"10.1016\/j.clim.2018.12.017_bb0075","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1178334","article-title":"Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells","volume":"327","author":"O'Shea","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.clim.2018.12.017_bb0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/361079a0","article-title":"T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-I\u03b2","volume":"361","author":"Tanaka","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.clim.2018.12.017_bb0090","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nri2654","article-title":"The functional plasticity of T cell subsets","volume":"9","author":"Bluestone","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.coi.2012.01.014","article-title":"Helper T cell diversity and plasticity","volume":"24","author":"Nakayamada","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.it.2013.01.001","article-title":"T follicular helper cell diversity and plasticity","volume":"34","author":"Cannons","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.immuni.2011.11.012","article-title":"Early Th1 cell differentiation is marked by a Tfh cell-like transition","volume":"35","author":"Nakayamada","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.12.017_bb0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1084\/jem.20151722","article-title":"IFN-\u03b3 receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity","volume":"213","author":"Domeier","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2018.12.017_bb0115","doi-asserted-by":"crossref","unstructured":"E. M. Tan, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum. 25 (1982) 1271\u20131277.","DOI":"10.1002\/art.1780251101"},{"key":"10.1016\/j.clim.2018.12.017_bb0120","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.12.017_bb0125","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"2010","key":"10.1016\/j.clim.2018.12.017_bb0130","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.clim.2018.12.017_bb0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"259","key":"10.1016\/j.clim.2018.12.017_bb0140","first-page":"927","article-title":"Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG)","volume":"69","author":"Symmons","year":"1998","journal-title":"Q. J. Med."},{"key":"10.1016\/j.clim.2018.12.017_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0022-1759(92)90228-L","article-title":"A new method for detachment of Dynabeads from positively selected B lymphocytes","volume":"146","author":"Rasmussen","year":"1992","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2018.12.017_bb0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clim.2007.10.004","article-title":"A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE","volume":"126","author":"Nicholas","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0155","doi-asserted-by":"crossref","first-page":"R1001","DOI":"10.1186\/ar1776","article-title":"Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"7","author":"Henneken","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.clim.2018.12.017_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058140","article-title":"Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice","volume":"8","author":"Lacotte","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clim.2018.12.017_bb0165","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ni.2294","article-title":"Differential Transcriptional programming of Class-specific B Cell memory by T-bet and ROR\u03b1","volume":"13","author":"Wang","year":"2012","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2018.12.017_bb0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.imbio.2008.10.004","article-title":"The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population","volume":"214","author":"Wu","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.clim.2018.12.017_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.clim.2018.12.017_bb0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2249.2004.02588.x","article-title":"Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis","volume":"138","author":"Calvani","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2018.12.017_bb0185","first-page":"36","article-title":"IFN-\u03b3, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus","volume":"36","author":"Wen","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2018.12.017_bb0190","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4049\/jimmunol.181.3.2211","article-title":"Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B","volume":"181","author":"Harigai","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.12.017_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.26","article-title":"Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway","volume":"5","author":"Oon","year":"2016","journal-title":"Clin Transl Immunology."},{"key":"10.1016\/j.clim.2018.12.017_bb0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferin-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2018.12.017_bb0205","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of Interferon-\u03b3 Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patient with Systemic Lupus","volume":"67","author":"Andrew","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2018.12.017_bb0210","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-\u03b3 Antibody, in patients with Discoid Lupus Erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:58:47Z","timestamp":1761494327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618304807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":42,"alternative-id":["S1521661618304807"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.12.017","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}